MaltSci 麦伴科研

Appearance

Popular Reports / translational-medicine

This report is written by MaltSci based on the latest literature and research findings

What are the challenges in clinical trial design? ​

Abstract ​

Clinical trials are crucial for evaluating new therapeutic interventions, yet their design is challenged by various factors that can compromise research validity and applicability. This review explores key challenges in clinical trial design, including the selection of appropriate study designs, participant recruitment and retention, regulatory and ethical considerations, data privacy and security, and addressing health disparities. The selection of study designs is critical, particularly in rare diseases and complex disorders, where disease heterogeneity complicates patient selection and endpoint identification. Recruitment and retention of participants remain significant hurdles, exacerbated by preferences for certain treatments and logistical barriers. Regulatory compliance and ethical considerations are paramount, especially when involving vulnerable populations. Furthermore, the increasing focus on patient-centered outcomes necessitates careful consideration of how these outcomes are measured and reported. Innovations in technology and data analytics present new opportunities to enhance clinical trial design, yet they also introduce challenges regarding data privacy and algorithmic biases. The review concludes by emphasizing the importance of collaborative efforts among researchers, regulatory bodies, and stakeholders to optimize clinical trial designs for future research endeavors. By addressing these multifaceted challenges, the clinical research community can ensure that trials effectively meet the evolving needs of patients and the healthcare system.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Key Challenges in Clinical Trial Design
    • 2.1 Selection of Appropriate Study Design
    • 2.2 Recruitment and Retention of Participants
    • 2.3 Regulatory and Ethical Considerations
    • 2.4 Managing Data Privacy and Security
    • 2.5 Addressing Diverse Populations and Health Disparities
  • 3 Innovations and Solutions
    • 3.1 Utilization of Adaptive Trial Designs
    • 3.2 Role of Technology and Data Analytics
    • 3.3 Strategies for Enhancing Participant Engagement
  • 4 Case Studies
    • 4.1 Successful Trials and Lessons Learned
    • 4.2 Trials that Faced Significant Challenges
  • 5 Future Directions in Clinical Trial Design
    • 5.1 Emerging Trends and Technologies
    • 5.2 Recommendations for Researchers and Stakeholders
  • 6 Summary

1 Introduction ​

Clinical trials are essential to the advancement of medical science, serving as the primary method for evaluating the safety and efficacy of new therapeutic interventions. Despite their critical role, the design of clinical trials is fraught with challenges that can hinder the validity and applicability of research findings. As the landscape of healthcare continues to evolve, understanding these challenges becomes increasingly important for researchers, regulatory bodies, and stakeholders in the medical community.

One of the most significant challenges in clinical trial design is the selection of an appropriate study design that aligns with the research question and trial objectives. Researchers must choose among various methodologies, including randomized controlled trials (RCTs), observational studies, and adaptive trial designs, each with its own strengths and limitations. The choice of study design directly impacts the trial's ability to detect treatment effects and generalize findings to broader populations[1][2]. Furthermore, the recruitment and retention of participants present substantial hurdles, particularly in diverse populations where demographic factors can significantly influence participation rates. Trials often struggle to achieve representative samples, leading to questions about the external validity of the findings[3].

Regulatory requirements and ethical considerations further complicate trial design. Researchers must navigate a complex landscape of regulations aimed at ensuring participant safety while maintaining scientific rigor. This balancing act is particularly challenging in studies involving vulnerable populations, such as children or individuals with rare diseases, where informed consent processes can be difficult to implement effectively[4][5]. Moreover, the increasing focus on patient-centered outcomes necessitates a careful consideration of how to measure and report these outcomes in a way that resonates with participants and stakeholders alike[6].

In recent years, advancements in technology and data analytics have introduced new opportunities to enhance clinical trial design. Innovations such as digital health tools, real-time data collection, and machine learning algorithms hold the potential to streamline recruitment processes, optimize trial logistics, and improve data management[7][8]. However, these technologies also present challenges, including data privacy concerns and the need for specialized expertise in data interpretation and analysis[9].

This review will systematically explore the multifaceted challenges in clinical trial design, focusing on key areas outlined in the report's structure. Section 2 will delve into the primary challenges, including the selection of appropriate study designs, recruitment and retention of participants, regulatory and ethical considerations, data privacy and security, and addressing health disparities in diverse populations. In Section 3, we will discuss recent innovations and solutions, such as adaptive trial designs and the role of technology in enhancing participant engagement. Section 4 will present case studies that illustrate both successful trials and those that faced significant challenges, providing valuable lessons for future research. Finally, Section 5 will outline future directions in clinical trial design, highlighting emerging trends and technologies, as well as offering recommendations for researchers and stakeholders.

By identifying and analyzing these key issues, this report aims to contribute to a deeper understanding of how to optimize clinical trial design for future research endeavors. The insights gleaned from this review will not only inform best practices but also help to foster an environment where clinical trials can more effectively address the evolving needs of patients and the healthcare system as a whole.

2 Key Challenges in Clinical Trial Design ​

2.1 Selection of Appropriate Study Design ​

Clinical trial design, particularly in the context of rare diseases and complex disorders, presents numerous challenges that can significantly impact the success of therapeutic development. These challenges include, but are not limited to, issues related to patient selection, endpoint identification, study duration, control group selection, and statistical analysis.

One major challenge is the heterogeneity of diseases, which complicates patient selection. In rare diseases such as propionic and methylmalonic acidemias, the variability in disease presentation makes it difficult to define a uniform patient population. This heterogeneity necessitates careful consideration of inclusion and exclusion criteria to ensure that the selected participants can adequately represent the target population (Vockley et al., 2023) [5].

The identification and selection of appropriate endpoints are critical as well. In the context of progressive multiple sclerosis (PMS), for example, determining the right target and outcome measures is particularly challenging in phase-2 studies. The complexity of the disease may require the use of both clinical and instrumental outcomes, which must be carefully evaluated to maximize the potential for detecting treatment effects (Pardini et al., 2017) [1].

Moreover, decisions regarding the duration of the study are pivotal. In organic acidemias, for instance, the duration must be sufficient to observe meaningful changes in outcomes, which can be complicated by the slow progression of the disease and the need for sensitive outcome measures (Vockley et al., 2023) [5].

The selection of control groups also poses a significant challenge. In rare diseases, natural history controls may be considered, but the appropriateness of such controls must be carefully evaluated to ensure they provide a valid comparison for assessing treatment effects. Additionally, the choice of statistical analyses must align with the specific characteristics of the patient population and the endpoints being measured, which can further complicate study design (Vockley et al., 2023) [5].

Collaboration with experts in the relevant disease area, along with regulatory and biostatistical guidance, is essential to navigate these challenges effectively. Engaging patients and their families early in the design process can also provide valuable insights that enhance the relevance and feasibility of the trial (Vockley et al., 2023) [5].

In summary, the design of clinical trials must account for a multitude of factors, including disease heterogeneity, endpoint selection, study duration, control group considerations, and statistical methodologies. Each of these elements plays a critical role in determining the overall success of the trial and the validity of its outcomes.

2.2 Recruitment and Retention of Participants ​

Recruitment and retention of participants in clinical trials represent significant challenges that can impact the overall success and validity of clinical research. Various studies have identified a range of issues that trial staff and investigators face in this regard.

One prominent challenge is the recruitment of eligible participants. According to a survey conducted among UK surgical trial staff, 60.3% of respondents identified a lack of eligible patients as a moderate or serious problem. Additionally, preferences for different treatments by patients (81.5%) and clinicians' time constraints (78.1%) were noted as common recruitment barriers. Clinicians also exhibited preferences for certain treatments, which affected their willingness to enroll patients in trials (76.8%) [10].

In the context of Alzheimer's disease clinical trials, recruitment and retention challenges are particularly acute. The complexities of selecting and retaining appropriate clinical trial subjects were highlighted during an international workshop organized to address these issues. Investigators face difficulties in ensuring timely completion of trials due to slow enrollment rates, which can prolong drug development and affect the applicability of trial results [[pmid:21784343],[pmid:21172069]].

Another study emphasized that effective recruitment and retention are crucial for deriving meaningful conclusions from clinical research. It noted that communication issues, generalizability concerns, and logistical challenges are common barriers. Strategies such as clear communication about the trial's purpose, addressing reasons for non-participation, and providing incentives can help mitigate these challenges [11].

Moreover, pediatric clinical trials face unique recruitment challenges. A lack of infrastructure for research in this demographic, coupled with ethical considerations regarding incentives and payments, complicates the recruitment process for children and their families [12].

Retention of participants is equally challenging, with issues such as participants forgetting to return questionnaires (81.4%) and finding participants ineligible for the trial (74.3%) being significant concerns. Long follow-up periods also contribute to retention difficulties, with 70.7% of respondents identifying this as a problem [10].

In summary, the key challenges in clinical trial design related to recruitment and retention include a lack of eligible participants, clinician and patient treatment preferences, communication barriers, logistical issues, and ethical considerations, particularly in pediatric trials. Addressing these challenges through strategic planning and implementation can enhance the effectiveness of clinical trials and improve participant engagement and retention.

2.3 Regulatory and Ethical Considerations ​

The design of clinical trials is a multifaceted process that faces several significant challenges, particularly in the context of regulatory and ethical considerations. These challenges can impact the effectiveness and integrity of clinical trials, influencing both the outcomes of the research and the welfare of the participants involved.

One of the primary challenges in clinical trial design is ensuring compliance with ethical standards and regulatory requirements. Clinical trials are among the most heavily regulated practices globally, with ethical principles such as autonomy, beneficence, and justice developed in response to historical medical atrocities. Regulations are established to protect the rights and welfare of human participants, thereby maintaining public trust in the research enterprise (Salhia & Olaiya, 2020). However, disparities in regulatory oversight can occur, particularly in low-resource nations, where the complexity of the regulatory environment and varying levels of regulatory maturity among different countries create significant hurdles. This lack of harmonization often results in inadequate protections for vulnerable populations, underscoring the need for better collaboration among national regulatory agencies (Salhia & Olaiya, 2020).

Another significant challenge pertains to the selection of appropriate patient populations and outcome measures. In studies focusing on progressive multiple sclerosis (PMS), for instance, the uncertainty surrounding the right target and outcome measures complicates the design of phase-2 studies. It is crucial to identify suitable instrumental and clinical outcomes that accurately reflect treatment efficacy, which can be particularly difficult in progressive disease contexts (Pardini et al., 2017). Moreover, in surgical trials, the ethics of sham surgery and the necessity for patient-important outcomes present additional design considerations that must be navigated carefully (Mundi et al., 2014).

Furthermore, logistical challenges, including maintaining protocol compliance and managing investigational products, pose significant barriers to successful trial execution. Clinical trial professionals, including principal investigators and clinical research coordinators, must contend with the evolving nature of clinical trials, which necessitates ongoing specialized training and clear role delineation (Peralta & Sánchez-Santiago, 2024). The complexity of clinical trials requires that all involved parties be adequately trained and supported to ensure data integrity and compliance with trial protocols.

Regulatory frameworks are also evolving to address these challenges, as seen in the recent updates to the International Council for Harmonization (ICH) Guideline for Good Clinical Practice (GCP). These updates emphasize a risk-proportionate approach to trial design, allowing for greater flexibility and innovation while safeguarding participant rights and the overall reliability of trial results (Grandinetti et al., 2025). The COVID-19 pandemic has further accelerated the adoption of decentralized trial elements and digital health technologies, presenting both opportunities and challenges in regulatory compliance and ethical considerations (Grandinetti et al., 2025).

In summary, the challenges in clinical trial design are multifaceted, encompassing regulatory, ethical, logistical, and methodological considerations. Addressing these challenges requires a collaborative approach among stakeholders, including regulatory agencies, researchers, and healthcare professionals, to ensure that clinical trials can be conducted ethically and effectively while advancing medical knowledge and improving patient outcomes.

2.4 Managing Data Privacy and Security ​

The design of clinical trials is pivotal in maximizing the potential to detect treatment effects, yet it is fraught with challenges, particularly in specialized fields such as progressive multiple sclerosis (PMS) studies. One of the foremost challenges in clinical trial design is the uncertainty regarding appropriate targets and outcomes, especially during phase-2 studies. The selection of patients, the choice of instrumental and clinical outcomes, and the overall design of the trials are critical aspects that must be addressed to ensure meaningful results (Pardini et al. 2017) [1].

Furthermore, managing data privacy and security poses significant hurdles in the realm of clinical trials. As the volume of data generated during trials increases, particularly with the advent of digital trials and the Internet of Things (IoT), protecting sensitive health information becomes paramount. Current methodologies often involve provisioning private user data to trusted trial investigators, yet this approach raises concerns regarding data confidentiality. There is a pressing need for architectures that secure the flow and control of personal data while maintaining the interests of all parties involved, especially during patient characterization and recruitment phases (Angeletti et al. 2018) [13].

In addition to privacy concerns, the sharing of patient-level data presents another layer of complexity. The pharmaceutical industry faces scrutiny over how to appropriately prepare and disseminate clinical trial data while ensuring patient confidentiality. While data reduction techniques can mitigate privacy risks, they must be balanced with the necessity of retaining data utility to facilitate meaningful scientific research. An excessive application of such techniques may lead to misleading results, which could pose public health risks (Tucker et al. 2016) [14].

Moreover, clinical trials must comply with Good Clinical Practice guidelines, which recommend robust data monitoring to ensure quality. However, the implementation of these monitoring procedures often encounters challenges, including adherence to regulatory requirements and effective use of technology. Researchers have reported difficulties in fostering collaborative relationships necessary for successful data quality monitoring (Houston et al. 2021) [15].

Overall, the challenges in clinical trial design are multifaceted, encompassing patient selection, outcome measurement, data privacy, and compliance with regulatory standards. Addressing these issues requires a comprehensive approach that includes enhanced training, standardized frameworks, and collaborative strategies to improve trial outcomes and the overall advancement of medical research.

2.5 Addressing Diverse Populations and Health Disparities ​

The design of clinical trials faces numerous challenges, particularly in the context of addressing diverse populations and health disparities. A critical issue is the lack of representation of racial and ethnic minority populations, which not only affects the generalizability of clinical trial results but also perpetuates health inequities. Historically, clinical trials have predominantly included middle-class, married white males, leading to a narrow understanding of treatment efficacy and safety across different demographic groups (Swanson & Ward, 1995) [16].

One of the primary challenges is the presence of both explicit and implicit biases within the healthcare system, which can influence the recruitment processes of clinical trials. Such biases may deter healthcare providers from enrolling diverse patient populations, as they may unconsciously prioritize participants who fit a more conventional profile (Pothuri et al., 2025) [17]. Additionally, language barriers and cultural nuances can complicate communication with potential participants, further hindering enrollment efforts (Odedina et al., 2024) [18].

Moreover, there are significant barriers at the organizational level that need to be addressed. Research organizations must implement systemic changes to promote diversity and inclusion in clinical trials. This includes developing tailored recruitment strategies that resonate with underrepresented communities and fostering partnerships with community organizations that can facilitate outreach (Mohan & Freedman, 2023) [19]. A lack of trust in the healthcare system among minority populations, often due to historical injustices, poses another substantial barrier to participation in clinical trials (Corneli et al., 2023) [20].

Eligibility criteria for trials often exclude individuals based on socioeconomic status, age, or comorbidities, which disproportionately affects minority groups (Islam et al., 2024) [21]. Adjusting these criteria to be more inclusive can enhance participation rates from diverse populations. Furthermore, decentralized trial designs, which leverage technology and remote monitoring, may also help in reducing barriers to access and participation (Kuaban et al., 2025) [3].

Lastly, there is a pressing need for comprehensive community engagement strategies that involve collaboration with community leaders and organizations. Such partnerships can help in understanding the unique barriers faced by diverse populations and in crafting culturally sensitive approaches to trial recruitment (Igwe et al., 2023) [22]. By addressing these multifaceted challenges, clinical trials can become more inclusive, ultimately leading to improved health outcomes and reduced disparities in healthcare access and treatment efficacy.

3 Innovations and Solutions ​

3.1 Utilization of Adaptive Trial Designs ​

Adaptive clinical trial designs present significant opportunities to optimize the conduct of clinical trials; however, they also introduce various challenges that must be addressed for effective implementation. One of the primary challenges is the complexity of these designs, which can increase the likelihood of bias and operational difficulties. As highlighted by Park et al. (2018), adaptive trials differ from conventional designs by allowing modifications during the trial based on accumulating data, which necessitates a thorough understanding of design features and potential sources of bias[23].

Regulatory concerns also pose a substantial challenge. In order for adaptive designs to be effectively utilized, National Regulatory Authorities (NRAs) must possess robust regulatory frameworks and the capacity to evaluate the increasingly complex methodologies that adaptive trials entail. Mahajan et al. (2025) emphasize that adaptive trials can provide earlier insights into safety and efficacy, thus enabling more responsive oversight; however, the regulatory landscape must evolve to accommodate these innovative designs[24].

Furthermore, logistical issues can impede the execution of adaptive trials. The experience shared by Parke (2011) indicates that despite the benefits of adaptive designs, the logistics of implementing such trials can be a barrier, particularly in phase 2 studies[25]. The need for real-time decision-making, dynamic surveillance, and the ability to adapt trial protocols can strain resources and require extensive planning and coordination.

Statistical considerations also play a crucial role in the challenges associated with adaptive trial designs. Chow and Chang (2008) point out that adaptations made during trials may lead to deviations from the originally targeted patient population, potentially affecting the type I error rate and the scientific validity of the trial outcomes[26]. Therefore, careful planning and prospective management of adaptations are essential to mitigate these risks.

Finally, while adaptive designs offer flexibility and efficiency, the clinical community's unfamiliarity with these methods can hinder their adoption. Burnett et al. (2020) note that despite the clear advantages outlined in the literature, the uptake of adaptive designs has been slow due to a lack of understanding of the various adaptations and their implications[27].

In conclusion, while adaptive trial designs hold promise for enhancing the efficiency and effectiveness of clinical trials, the associated challenges—including regulatory, logistical, statistical, and educational barriers—must be carefully navigated to realize their full potential in clinical research.

3.2 Role of Technology and Data Analytics ​

Clinical trial design faces numerous challenges that can significantly impede the efficiency and effectiveness of the research process. Key issues include recruitment delays, escalating costs, data quality concerns, and the complexity of managing diverse data sources. Specifically, recruitment delays affect approximately 80% of studies, with the costs of pharmaceutical research and development exceeding $200 billion annually, and success rates for trials falling below 12% [28]. Additionally, data quality issues compromise 50% of datasets, creating further obstacles in the trial process [28].

One of the major challenges is the traditional approach to clinical trials, which often results in logistical barriers to participant engagement and retention. The conventional trial designs can be inefficient and may not fully utilize modern technological advancements. The complexity of these trials is compounded by the need for precise data collection and the integration of various technologies, which can lead to fragmented systems that limit evidence generation [29].

In response to these challenges, innovative solutions leveraging technology and data analytics are being explored. The advent of digital clinical trials represents a transformative approach that utilizes digital technology to enhance participant access, engagement, and data collection [30]. Digital tools can facilitate concealed randomization, improve the efficiency of trial-related measurements, and lower costs [30]. For instance, decentralized trials that incorporate digital health solutions have shown promise in enhancing recruitment and retention by providing more flexible participation options for patients [31].

Moreover, artificial intelligence (AI) and machine learning are emerging as critical components in addressing inefficiencies within the clinical trial lifecycle. AI technologies can enhance patient recruitment by improving enrollment rates by up to 65% and can provide predictive analytics with up to 85% accuracy in forecasting trial outcomes [28]. The integration of AI has the potential to accelerate trial timelines by 30-50% and reduce costs by as much as 40% [28].

Despite these innovations, several implementation barriers remain. Challenges include ensuring data interoperability, addressing regulatory uncertainties, and mitigating algorithmic biases [28]. There is also a need for a robust regulatory framework to guide the ethical use of AI in clinical trials, which is essential for maintaining patient safety and scientific integrity [28].

The application of advanced technologies such as wearable devices also presents both opportunities and challenges. While these devices can enhance data collection and patient monitoring, they require careful consideration of methodological and logistical factors to ensure their effectiveness in clinical trials [32].

In summary, the challenges in clinical trial design are multifaceted, encompassing recruitment issues, high costs, and data quality concerns. However, innovations in technology and data analytics, particularly through digital clinical trials and the application of AI, offer promising solutions to enhance the efficiency and effectiveness of clinical research. Addressing the barriers to implementation and ensuring a robust regulatory framework will be crucial in realizing the full potential of these advancements.

3.3 Strategies for Enhancing Participant Engagement ​

Clinical trial design faces numerous challenges that can significantly impact participant engagement and overall trial success. These challenges arise from various perspectives, including those of physicians, patients, healthcare systems, and trial-related factors.

One of the primary challenges is the recruitment of a representative participant population. Traditional clinical trials have often failed to attract diverse groups, with only about 5% of eligible patients participating in research. Barriers such as geographical constraints, mistrust, miscommunication, and discrimination are frequently cited by potential participants, particularly those from minority groups[33]. This lack of inclusivity can exacerbate health disparities and limit the generalizability of trial results.

In the context of specific diseases, such as Parkinson's disease (PD), underrepresented minorities, older patients, and those with multiple medical comorbidities are particularly less likely to enroll in clinical trials. This underrepresentation can delay trial completion and hinder the ability to draw comprehensive conclusions from the data[34]. Efforts to improve trial design and recruitment are essential, which may include broadening inclusion criteria, minimizing participant burden, and enhancing trial efficiency.

The emergence of decentralized clinical trials (DCTs) has been proposed as a potential solution to some of these challenges. DCTs aim to reduce barriers by allowing participants to engage in trials from their homes, thereby addressing issues related to travel and logistical constraints. However, the implementation of DCTs also introduces new complexities, such as the digital divide, the exclusion of certain tests and procedures, and the need for new infrastructure to support at-home medication delivery[33].

Moreover, enhancing patient involvement in clinical trial design can lead to better recruitment and retention rates. Trials that consider the perspectives and needs of patients—such as incorporating patient-reported outcomes—tend to be more relevant and impactful. However, there is still limited involvement of patients in the design and conduct of trials, particularly in fields like nephrology[35]. Engaging patients throughout the trial process, from priority setting to study design and dissemination, can ensure that trials address their concerns and priorities effectively.

Strategies to enhance participant engagement also include leveraging digital healthcare technologies, utilizing real-world data and evidence, and employing pragmatic trial designs. These approaches aim to create a more inclusive and participant-friendly environment that encourages enrollment and retention, especially among underrepresented groups[36].

In conclusion, addressing the multifaceted challenges in clinical trial design requires innovative strategies that prioritize participant inclusivity and engagement. By understanding and mitigating barriers to participation, researchers can enhance the quality and generalizability of clinical research, ultimately leading to better health outcomes for diverse patient populations.

4 Case Studies ​

4.1 Successful Trials and Lessons Learned ​

Clinical trial design presents a multitude of challenges that can significantly impact the success of studies across various medical fields. These challenges are often compounded by the specific characteristics of the diseases being studied, the patient populations involved, and the regulatory environments governing clinical research.

One primary challenge is the inherent disease heterogeneity observed in many conditions, particularly in rare diseases and progressive conditions such as propionic and methylmalonic acidemias. The diversity in disease presentation complicates patient selection and endpoint identification, as noted by Vockley et al. (2023), who emphasize the need for sensitive outcome measures and the importance of engaging with experts to navigate these complexities effectively[5].

In progressive multiple sclerosis (PMS) trials, the uncertainty regarding the appropriate targets and outcomes in phase-2 studies poses additional difficulties. The selection of patients and outcomes must be carefully evaluated to maximize the potential for detecting treatment effects, as highlighted by Pardini et al. (2017) in their review of clinical trial design challenges in PMS[1].

The incorporation of big data analytics into clinical trial design also presents both opportunities and challenges. While big data systems can enhance trial efficiency and support better decision-making, they introduce complexities related to data standardization, ethical considerations, and the management of confounding factors[37]. Furthermore, trials in oncology must adapt to rapid advancements in technology and molecular profiling, which necessitate innovative trial designs such as master protocols that can test multiple treatments simultaneously[38].

Moreover, the recruitment of participants remains a significant hurdle across various clinical trials. Studies have shown that recruitment challenges account for a large proportion of non-completed trials, with attrition rates differing based on the condition being studied[39]. The need for diverse and representative patient populations in clinical trials is underscored by initiatives aimed at integrating diversity, equity, and inclusion into trial design, as discussed by Kuaban et al. (2025)[3].

Finally, the ethical implications of trial design, particularly in vulnerable populations, must be carefully considered. This includes addressing implicit biases that may affect patient enrollment and ensuring that trial designs do not compromise the patient-physician relationship, a concern raised in discussions of randomized trials in chronic diseases like breast cancer[40].

In summary, successful clinical trial design must navigate a landscape fraught with challenges, including disease heterogeneity, recruitment difficulties, and ethical considerations. Lessons learned from various case studies highlight the importance of innovative approaches, expert engagement, and the integration of big data to enhance trial design and execution.

4.2 Trials that Faced Significant Challenges ​

Clinical trial design is fraught with numerous challenges that can significantly impact the outcomes and efficacy of the studies. These challenges can be observed in various contexts, as highlighted by several case studies in the literature.

One notable challenge is the difficulty in selecting appropriate patient populations and outcome measures. In the context of progressive multiple sclerosis (PMS), for instance, the uncertainty regarding the right target and/or outcome in phase-2 studies poses a significant hurdle. The design of clinical trials in PMS is particularly complicated due to the need to maximize the possibility of detecting treatment effects while navigating these uncertainties. Issues related to patient selection and the instrumental and clinical outcomes that can be utilized in PMS trials have been extensively discussed, indicating a pressing need for improved methodologies in trial design (Pardini et al., 2017) [1].

Moreover, in the realm of rheumatoid arthritis, Ortiz et al. (1997) emphasized that the considerations in designing clinical trials for novel molecules are akin to those encountered in any rheumatoid arthritis clinical trial. Critical issues arise regarding outcome measures, patient populations, and the characteristics of study designs. While some challenges have been addressed through consensus, the necessity for further research to support diverse measurement techniques remains apparent [41].

The design and implementation of clinical trials for major depressive disorder (MDD) also reveal significant challenges. Rapaport and Maddux (2002) highlighted that many conventional trials are built upon theoretical assumptions that may not hold true in practice. This discrepancy raises questions about the validity of these assumptions and suggests that alternative constructs may be necessary to differentiate drug-placebo effects more effectively [42].

In the context of vaccine development, particularly for COVID-19, the urgency of rapid vaccine development has introduced unique challenges. A consensus report by Lambert et al. (2020) indicated that while there has been an unprecedented rapid response by vaccine developers, a major concern remains the avoidance of safety issues, such as "disease enhancement," which has been previously observed with other viral vaccines. The need for thoughtful vaccine design and thorough evaluation in a timely manner underscores the complexities faced in trial design during a pandemic [43].

Finally, the landscape of clinical trials involving pregnant individuals presents its own set of challenges. Schreiber et al. (2024) noted that pregnant individuals are often excluded from premarketing trials, leading to a significant gap in data regarding the effectiveness and safety of therapeutics during pregnancy. The reluctance of pharmaceutical companies and regulatory bodies to include pregnant individuals in studies stems from historical concerns about the risks involved, further complicating the design of trials that aim to understand drug effects in this population [44].

These case studies illustrate that the challenges in clinical trial design are multifaceted, involving patient selection, outcome measurement, theoretical assumptions, safety concerns, and ethical considerations. Addressing these challenges is crucial for the advancement of clinical research and the successful implementation of new therapeutic interventions.

5 Future Directions in Clinical Trial Design ​

5.1 Emerging Trends and Technologies ​

Clinical trial design faces numerous challenges that can significantly impact the efficacy and efficiency of research in various medical fields. These challenges are particularly pronounced in the context of rare diseases, complex conditions, and innovative therapeutic approaches.

One major challenge is the heterogeneity of disease presentations, which complicates patient selection and endpoint identification. For instance, in organic acidemias such as propionic and methylmalonic acidemias, the variability in patient symptoms and disease progression necessitates careful consideration of endpoints and control groups to accurately assess treatment responses (Vockley et al., 2023) [5]. Additionally, the requirement for sensitive outcome measures and the difficulty in recruiting a sufficient number of participants are prevalent issues in trials for rare diseases (Vockley et al., 2023).

In progressive multiple sclerosis (PMS) studies, the uncertainty regarding appropriate targets and outcomes adds complexity to trial design. The selection of patients and the determination of instrumental and clinical outcomes are critical to maximizing the potential for detecting treatment effects (Pardini et al., 2017) [1]. This reflects a broader trend in clinical research where traditional methodologies must adapt to the nuances of various conditions.

Moreover, the emergence of big data analytics presents both opportunities and challenges. While these resources can enhance trial design and facilitate better recruitment strategies, they also introduce complications related to data standardization and the integration of diverse data sources (Mayo et al., 2017) [37]. The need for robust statistical methodologies to manage and interpret large datasets is paramount, as is the necessity to address ethical concerns regarding patient privacy and data usage.

Innovative trial designs, such as adaptive designs and master protocols, have been proposed to improve the flexibility and efficiency of clinical trials. Adaptive designs allow for modifications based on interim results, potentially leading to more ethical and resource-efficient studies (Pallmann et al., 2018) [45]. However, the implementation of such designs requires a thorough understanding of their complexities and implications for data interpretation and regulatory approval.

The incorporation of new technologies, such as circulating tumor DNA (ctDNA) in oncology trials, exemplifies how advancements can streamline trial processes and improve outcomes (Lam et al., 2018) [38]. Nevertheless, these innovations also necessitate rigorous validation and the establishment of new standards for trial conduct and reporting.

Furthermore, addressing diversity, equity, and inclusion in clinical trials remains a critical challenge. Efforts to harmonize demographic terminology and engage communities throughout the trial process are essential to ensure that research outcomes are representative and applicable to broader populations (Kuaban et al., 2025) [3].

In summary, the landscape of clinical trial design is evolving, marked by both significant challenges and promising innovations. Future directions must focus on enhancing methodological rigor, leveraging emerging technologies, and fostering inclusive practices to ensure that clinical research can effectively address the complexities of modern medicine. As the field progresses, continuous adaptation and collaboration among stakeholders will be crucial to overcoming these challenges and optimizing clinical trial outcomes.

5.2 Recommendations for Researchers and Stakeholders ​

The challenges in clinical trial design are multifaceted and vary across different therapeutic areas. A comprehensive understanding of these challenges is essential for researchers and stakeholders involved in the development of clinical trials.

One significant challenge is the design of trials that maximize the potential to detect treatment effects, particularly in complex conditions such as progressive multiple sclerosis (PMS). The uncertainty regarding appropriate targets and outcomes complicates phase-2 studies in PMS trials, necessitating careful selection of patient populations and outcomes that can be utilized effectively [1].

Moreover, the traditional sequential clinical trial phases have become increasingly strained due to the rise in novel therapies, which has led to issues such as prolonged development times, significant costs, and difficulties in testing therapies for rarer tumors. This has prompted the emergence of novel clinical trial designs aimed at improving efficiencies in trial conduct and better evaluating the benefits of new drugs in neuro-oncology [46]. The regulatory process is also evolving to accommodate these innovations, highlighting the need for flexibility and adaptation in trial designs [47].

In addition to these specific challenges, there are overarching issues that affect clinical trials across various domains. For instance, the integration of new technologies and data sources into trial designs necessitates a shift in regulatory frameworks to ensure participant safety and trial reliability while promoting innovation [47]. The need for risk-proportionate approaches to trial design and conduct is increasingly recognized, which calls for a balance between safeguarding participant rights and expediting the development of effective therapies [47].

Future directions in clinical trial design should focus on addressing these challenges through innovative methodologies. Emphasizing patient-centered approaches, leveraging real-world data, and incorporating adaptive trial designs can enhance the relevance and efficiency of clinical trials [9]. Additionally, as diseases are increasingly recognized as heterogeneous, trial designs must reflect this diversity, allowing for more tailored therapeutic interventions [9].

For researchers and stakeholders, it is crucial to engage in timely communication with regulatory agencies to align trial designs with current standards and expectations. This collaboration can foster the development of guidelines that facilitate the adoption of innovative trial designs while ensuring robust scientific rigor [2]. Furthermore, addressing attitudinal barriers among stakeholders regarding the value and purpose of clinical practice guidelines is essential to enhance the implementation of effective trial designs [48].

In summary, the challenges in clinical trial design are significant and evolving, requiring a proactive and collaborative approach among researchers, regulatory bodies, and stakeholders. By embracing innovation and fostering open communication, the clinical research landscape can advance towards more effective and efficient trial designs that ultimately improve patient outcomes.

6 Conclusion ​

The landscape of clinical trial design is characterized by multifaceted challenges that require comprehensive strategies to enhance the validity and applicability of research findings. Key findings from this review indicate that the selection of appropriate study designs, recruitment and retention of participants, and navigating regulatory and ethical considerations are paramount for successful trial execution. Current trends highlight the importance of adaptive trial designs and the integration of technology to streamline processes and improve participant engagement. However, persistent issues related to diversity and health disparities in clinical trials underscore the need for systemic changes to ensure inclusive research practices. Future directions should focus on leveraging emerging technologies, fostering collaboration among stakeholders, and developing innovative methodologies that reflect the complexities of modern medicine. By addressing these challenges proactively, the clinical research community can optimize trial designs and ultimately enhance patient outcomes across diverse populations.

References ​

  • [1] Matteo Pardini;Gary Cutter;Maria Pia Sormani. Clinical trial design for progressive MS trials.. Multiple sclerosis (Houndmills, Basingstoke, England)(IF=5.0). 2017. PMID:29041873. DOI: 10.1177/1352458517729461.
  • [2] Daohong Chen;Eric Yining Qi. Innovative highlights of clinical drug trial design.. Translational research : the journal of laboratory and clinical medicine(IF=5.9). 2020. PMID:32504825. DOI: 10.1016/j.trsl.2020.05.007.
  • [3] Alice Kuaban;Alysha K Croker;Jeffrey Keefer;Leonard A Valentino;Barbara E Bierer;Stephen Boateng;Donna DiMichele;Patrick Fogarty;C Michael Gibson;Anna M Hood;Lloryn Hubbard;Antonella Isgrò;Karin Knobe;Leslie Lake;Iman Martin;Michel Reid;Jonathan C Roberts;Wendy Tomlinson;Lanre Tunji-Ajayi;Harriette G C Van Spall;Caroline Voltz-Girolt;Allison P Wheeler;Alan E Mast;Stephanie Seremetis. The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative.. Blood advances(IF=7.1). 2025. PMID:39652409. DOI: 10.1182/bloodadvances.2024013945.
  • [4] Marijke C Jansen-van der Weide;Patrina H Y Caldwell;Bridget Young;Martine C de Vries;Dick L Willems;William Van't Hoff;Kerry Woolfall;Johanna H van der Lee;Martin Offringa. Clinical Trial Decisions in Difficult Circumstances: Parental Consent Under Time Pressure.. Pediatrics(IF=6.4). 2015. PMID:26416935. DOI: 10.1542/peds.2014-3402.
  • [5] Jerry Vockley;Barbara Burton;Agnieszka Jurecka;Jitendra Ganju;Beth Leiro;Roberto Zori;Nicola Longo. Challenges and strategies for clinical trials in propionic and methylmalonic acidemias.. Molecular genetics and metabolism(IF=3.5). 2023. PMID:37245378. DOI: 10.1016/j.ymgme.2023.107612.
  • [6] Jamal Mikdashi;Ola Nived. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research.. Arthritis research & therapy(IF=4.6). 2015. PMID:26189728. DOI: 10.1186/s13075-015-0702-6.
  • [7] Shahzadgai Khan;Muna Albayaty;James Bush;Joseph Cheriyan;Anthea Cromie;Annelize Koch;Michael Hammond;Stuart Mair;Ulrike Lorch;Steffan Stringer;Jorg Taubel;Timothy C Hardman. The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges.. Frontiers in pharmacology(IF=4.8). 2020. PMID:33364955. DOI: 10.3389/fphar.2020.580560.
  • [8] Sarah C Montembeau;Birju R Rao;Andrea R Mitchell;Candace D Speight;Larry A Allen;Scott D Halpern;Yi-An Ko;Daniel D Matlock;Miranda A Moore;Alanna A Morris;Laura D Scherer;Peter Ubel;Neal W Dickert. Integrating Cost into Shared Decision-Making for Heart Failure with Reduced Ejection Fraction (POCKET-COST-HF): A Trial Providing Out-of-Pocket Costs for Heart Failure Medications during Clinical Encounters.. American heart journal(IF=3.5). 2024. PMID:38096946. DOI: 10.1016/j.ahj.2023.11.013.
  • [9] D A Berry. Emerging innovations in clinical trial design.. Clinical pharmacology and therapeutics(IF=5.5). 2016. PMID:26561040. DOI: 10.1002/cpt.285.
  • [10] J C Crocker;N Farrar;J A Cook;S Treweek;K Woolfall;A Chant;J Bostock;L Locock;S Rees;S Olszowski;R Bulbulia. Recruitment and retention of participants in UK surgical trials: survey of key issues reported by trial staff.. BJS open(IF=4.5). 2020. PMID:33016008. DOI: 10.1002/bjs5.50345.
  • [11] Leonie Klompstra;Anna Strömberg;Tiny Jaarsma;Jeroen M Hendriks. Challenges and strategies for effective recruitment and retention of participants in clinical research studies.. European journal of cardiovascular nursing(IF=3.9). 2025. PMID:39749483. DOI: 10.1093/eurjcn/zvae158.
  • [12] Carl L Tishler;Natalie Staats Reiss. Pediatric drug-trial recruitment: enticement without coercion.. Pediatrics(IF=6.4). 2011. PMID:21464193. DOI: 10.1542/peds.2010-2585.
  • [13] Fabio Angeletti;Ioannis Chatzigiannakis;Andrea Vitaletti. Towards an Architecture to Guarantee Both Data Privacy and Utility in the First Phases of Digital Clinical Trials.. Sensors (Basel, Switzerland)(IF=3.5). 2018. PMID:30487435. DOI: 10.3390/s18124175.
  • [14] Katherine Tucker;Janice Branson;Maria Dilleen;Sally Hollis;Paul Loughlin;Mark J Nixon;Zoë Williams. Protecting patient privacy when sharing patient-level data from clinical trials.. BMC medical research methodology(IF=3.4). 2016. PMID:27410040. DOI: 10.1186/s12874-016-0169-4.
  • [15] Lauren Houston;Ping Yu;Allison Martin;Yasmine Probst. Clinical researchers' lived experiences with data quality monitoring in clinical trials: a qualitative study.. BMC medical research methodology(IF=3.4). 2021. PMID:34544365. DOI: 10.1186/s12874-021-01385-9.
  • [16] G M Swanson;A J Ward. Recruiting minorities into clinical trials: toward a participant-friendly system.. Journal of the National Cancer Institute(IF=7.2). 1995. PMID:7473831. DOI: 10.1093/jnci/87.23.1747.
  • [17] Bhavana Pothuri;Premal Thaker;Adrienne Moore;Rosa Espinosa;Kara Medina;Deborah Collyar;Kathleen Lutz;Mihaela C Munteanu;Brian Slomovitz. Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel.. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society(IF=4.7). 2025. PMID:39277183. DOI: 10.1136/ijgc-2024-005751.
  • [18] Folakemi T Odedina;Mark L Wieland;Kim Barbel-Johnson;Jennifer M Crook. Community Engagement Strategies for Underrepresented Racial and Ethnic Populations.. Mayo Clinic proceedings(IF=6.7). 2024. PMID:38176825. DOI: 10.1016/j.mayocp.2023.07.015.
  • [19] Shalini V Mohan;Jamie Freedman. A Review of the Evolving Landscape of Inclusive Research and Improved Clinical Trial Access.. Clinical pharmacology and therapeutics(IF=5.5). 2023. PMID:36536992. DOI: 10.1002/cpt.2832.
  • [20] Amy Corneli;Emily Hanlen-Rosado;Kevin McKenna;Richardae Araojo;Dawn Corbett;Kaveeta Vasisht;Bernadette Siddiqi;Tesheia Johnson;Luther T Clark;Sara B Calvert. Enhancing Diversity and Inclusion in Clinical Trials.. Clinical pharmacology and therapeutics(IF=5.5). 2023. PMID:36628990. DOI: 10.1002/cpt.2819.
  • [21] Nadia Islam;Laura Budvytyte;Nandita Khera;Talal Hilal. Disparities in Clinical Trial Enrollment- Focus on CAR-T and Bispecific Antibody Therapies.. Current hematologic malignancy reports(IF=3.3). 2024. PMID:39630328. DOI: 10.1007/s11899-024-00747-6.
  • [22] Joseph-Kevin Igwe;Tenzin Yeshi Wangdak Yuthok;Erin Cruz;Adrienne Mueller;Roy Hao Lan;Cati Brown-Johnson;Muhammed Idris;Fatima Rodriguez;Kira Clark;Latha Palaniappan;Melvin Echols;Paul Wang;Anekwe Onwuanyi;Priscilla Pemu;Eldrin F Lewis. Opportunities to Increase Science of Diversity and Inclusion in Clinical Trials: Equity and a Lack of a Control.. Journal of the American Heart Association(IF=5.3). 2023. PMID:38108253. DOI: 10.1161/JAHA.123.030042.
  • [23] Jay Jh Park;Kristian Thorlund;Edward J Mills. Critical concepts in adaptive clinical trials.. Clinical epidemiology(IF=3.2). 2018. PMID:29606891. DOI: 10.2147/CLEP.S156708.
  • [24] Manish Mahajan;Laura B Martin;Kumar Gaurav;Rajinder Kumar Suri. Adaptive clinical trial designs for rapid vaccine development: Developing country vaccine manufacturers' perspective.. Vaccine(IF=3.5). 2025. PMID:41176966. DOI: 10.1016/j.vaccine.2025.127890.
  • [25] Tom Parke. ISCTM: Implementing phase 2 dose finding adaptive clinical trials.. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology(IF=6.7). 2011. PMID:20947316. DOI: 10.1016/j.euroneuro.2010.09.005.
  • [26] Shein-Chung Chow;Mark Chang. Adaptive design methods in clinical trials - a review.. Orphanet journal of rare diseases(IF=3.5). 2008. PMID:18454853. DOI: 10.1186/1750-1172-3-11.
  • [27] Thomas Burnett;Pavel Mozgunov;Philip Pallmann;Sofia S Villar;Graham M Wheeler;Thomas Jaki. Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs.. BMC medicine(IF=8.3). 2020. PMID:33208155. DOI: 10.1186/s12916-020-01808-2.
  • [28] David B Olawade;Sandra Chinaza Fidelis;Sheila Marinze;Eghosasere Egbon;Ayodele Osunmakinde;Augustus Osborne. Artificial intelligence in clinical trials: A comprehensive review of opportunities, challenges, and future directions.. International journal of medical informatics(IF=4.1). 2026. PMID:41075423. DOI: 10.1016/j.ijmedinf.2025.106141.
  • [29] Joseph B Franklin;Caroline Marra;Kaleab Z Abebe;Atul J Butte;Deborah J Cook;Laura Esserman;Lee A Fleisher;Cynthia I Grossman;Nancy E Kass;Harlan M Krumholz;Kathy Rowan;Amy P Abernethy; . Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence.. JAMA(IF=55.0). 2024. PMID:39102333. DOI: 10.1001/jama.2024.0268.
  • [30] O T Inan;P Tenaerts;S A Prindiville;H R Reynolds;D S Dizon;K Cooper-Arnold;M Turakhia;M J Pletcher;K L Preston;H M Krumholz;B M Marlin;K D Mandl;P Klasnja;B Spring;E Iturriaga;R Campo;P Desvigne-Nickens;Y Rosenberg;S R Steinhubl;R M Califf. Digitizing clinical trials.. NPJ digital medicine(IF=15.1). 2020. PMID:32821856. DOI: 10.1038/s41746-020-0302-y.
  • [31] Ojasav Sehrawat;Peter A Noseworthy;Konstantinos C Siontis;Tufia C Haddad;John D Halamka;Hongfang Liu. Data-Driven and Technology-Enabled Trial Innovations Toward Decentralization of Clinical Trials: Opportunities and Considerations.. Mayo Clinic proceedings(IF=6.7). 2023. PMID:37661149. DOI: 10.1016/j.mayocp.2023.02.003.
  • [32] Elena S Izmailova;John A Wagner;Eric D Perakslis. Wearable Devices in Clinical Trials: Hype and Hypothesis.. Clinical pharmacology and therapeutics(IF=5.5). 2018. PMID:29205294. DOI: 10.1002/cpt.966.
  • [33] Noah Goodson;Paul Wicks;Jayne Morgan;Leen Hashem;Sinéad Callinan;John Reites. Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion.. NPJ digital medicine(IF=15.1). 2022. PMID:35513479. DOI: 10.1038/s41746-022-00603-y.
  • [34] Pavan A Vaswani;Thomas F Tropea;Nabila Dahodwala. Overcoming Barriers to Parkinson Disease Trial Participation: Increasing Diversity and Novel Designs for Recruitment and Retention.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics(IF=6.9). 2020. PMID:33150545. DOI: 10.1007/s13311-020-00960-0.
  • [35] Allison Tong;Nicole Scholes-Robertson;Carmel Hawley;Andrea K Viecelli;Simon A Carter;Adeera Levin;Brenda R Hemmelgarn;Tess Harris;Jonathan C Craig. Patient-centred clinical trial design.. Nature reviews. Nephrology(IF=39.8). 2022. PMID:35668231. DOI: 10.1038/s41581-022-00585-w.
  • [36] Jie Chen;Ying Lu;Shivaani Kummar. Increasing patient participation in oncology clinical trials.. Cancer medicine(IF=3.1). 2023. PMID:36043431. DOI: 10.1002/cam4.5150.
  • [37] Charles S Mayo;Martha M Matuszak;Matthew J Schipper;Shruti Jolly;James A Hayman;Randall K Ten Haken. Big Data in Designing Clinical Trials: Opportunities and Challenges.. Frontiers in oncology(IF=3.3). 2017. PMID:28913177. DOI: 10.3389/fonc.2017.00187.
  • [38] Michael Lam;Jonathan M Loree;Allan Anderson Lima Pereira;Yun Shin Chun;Scott Kopetz. Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.. Current treatment options in oncology(IF=4.7). 2018. PMID:29488033. DOI: 10.1007/s11864-018-0524-2.
  • [39] M Soledad Cepeda;Victor Lobanov;Jesse A Berlin. Use of ClinicalTrials.gov to estimate condition-specific nocebo effects and other factors affecting outcomes of analgesic trials.. The journal of pain(IF=4.0). 2013. PMID:23453563. DOI: .
  • [40] M Zelen. Innovations in the design of clinical trials in breast cancer.. Breast cancer research and treatment(IF=3.0). 1983. PMID:6616074. DOI: 10.1007/BF01803556.
  • [41] Z Ortiz;P Tugwell;D Yocum. The design of clinical trials aimed at assessing the DC-ART properties of new molecules in rheumatoid arthritis.. Clinical and experimental rheumatology(IF=3.3). 1997. PMID:9266131. DOI: .
  • [42] Mark H Rapaport;Rachel E Maddux. Challenges in the development of clinical trials for major depressive disorder: lessons learned from trials in minor depression.. Dialogues in clinical neuroscience(IF=8.9). 2002. PMID:22034443. DOI: .
  • [43] Paul-Henri Lambert;Donna M Ambrosino;Svein R Andersen;Ralph S Baric;Steven B Black;Robert T Chen;Cornelia L Dekker;Arnaud M Didierlaurent;Barney S Graham;Samantha D Martin;Deborah C Molrine;Stanley Perlman;Philip A Picard-Fraser;Andrew J Pollard;Chuan Qin;Kanta Subbarao;Jakob P Cramer. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.. Vaccine(IF=3.5). 2020. PMID:32507409. DOI: 10.1016/j.vaccine.2020.05.064.
  • [44] Karen Schreiber;Christine Graversgaard;Beverley J Hunt;James M S Wason;Nathalie Costedoat-Chalumeau;Silvia Aguilera;Marta M Guerra;Jane E Salmon. Challenges of designing and conducting cohort studies and clinical trials in populations of pregnant people.. The Lancet. Rheumatology(IF=16.4). 2024. PMID:38876128. DOI: 10.1016/S2665-9913(24)00118-8.
  • [45] Philip Pallmann;Alun W Bedding;Babak Choodari-Oskooei;Munyaradzi Dimairo;Laura Flight;Lisa V Hampson;Jane Holmes;Adrian P Mander;Lang'o Odondi;Matthew R Sydes;Sofía S Villar;James M S Wason;Christopher J Weir;Graham M Wheeler;Christina Yap;Thomas Jaki. Adaptive designs in clinical trials: why use them, and how to run and report them.. BMC medicine(IF=8.3). 2018. PMID:29490655. DOI: 10.1186/s12916-018-1017-7.
  • [46] Anurag Saraf;Lorenzo Trippa;Rifaquat Rahman. Novel Clinical Trial Designs in Neuro-Oncology.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics(IF=6.9). 2022. PMID:35969361. DOI: 10.1007/s13311-022-01284-x.
  • [47] Cheryl Grandinetti;Mandy Budwal-Jagait;Hocine Abid;Emily Gebbia;Elena Boley;LaKisha Williams;Andrew Fisher;Leigh Marcus;Laurie Muldowney;Jenn Sellers;Jason Wakelin-Smith;Kassa Ayalew. Evolving Standards: Good Clinical Practice Insights from US FDA, MHRA UK, and Health Canada.. Clinical pharmacology and therapeutics(IF=5.5). 2025. PMID:41194530. DOI: 10.1002/cpt.70120.
  • [48] G P Browman. Improving clinical practice guidelines for the 21st century. Attitudinal barriers and not technology are the main challenges.. International journal of technology assessment in health care(IF=3.1). 2000. PMID:11155844. DOI: 10.1017/s0266462300103034.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Clinical Trial Design · Participant Recruitment · Ethical Considerations · Data Privacy · Health Disparities

© 2025 MaltSci